Ophthalmology & Visual Sciences at the Eye Institute

Ongoing Study - Not Currently Enrolling

Alcon HAWK Study for Neovascular Age-Related Macular Degeneration (Wet AMD)

Purpose of study:

This research study is being done to see how safe and effective a drug called RTH258 is in treating neovascular age-related macular degeneration, or “Wet” AMD. RTH258 will be compared to a drug called Eylea®, which is already FDA-approved for treatment of Wet AMD.

What is Wet AMD?

Age-related macular degeneration (AMD) is a disease that blurs the sharp, central vision you need for “straight-ahead” activities such as reading, sewing, and driving. The retina is the thin tissue at the back of the eye that contains light-sensitive cells that allow you to see. The choroid lies under the retina and contains many small blood vessels that provide oxygen and nutrition to the retina. The choroid sometimes responds to age-related changes and inflammation by growing abnormal blood vessels under the retina. Leakage from such vessels causes swelling of the retina, leading to a serious loss of central vision.

What is involved?

The study will last about 2 years with up to 26 study visits at the Eye Institute. 2 out of 3 people who participate in the study will be randomly assigned to receive RTH258, and 1 out of 3 people will receive Eylea®. Participants will not be told which group they have been assigned to.


Research volunteers will receive $50 for each study visit that they complete.

You may be eligible to participate in this study if you meet these criteria.

  1. An eye doctor has told you that you have Wet AMD (will be confirmed by a study doctor). 
  2. You are 50 years of age or older.
  3. You have not previously received any treatment for Wet AMD, excluding vitamin supplements, in the study eye.
  4. You have not received a steroid injection in the study eye.
  5. You have not had any eye surgery in the study eye.
  6. You have not had a stroke or heart attack within the past 3 months.

  More Information:

Additional information about the Alcon HAWK study can be found at ClinicalTrials.gov.

IRB Approval: PRO00024620, 6/1/2015

Contact Ophthalmology

For patient care inquires, call us at (414) 955-2020 or use MyChart. Email is for research and education inquiries only.

Eye Institute Location

925 N. 87th St.

Milwaukee, WI 53226



(414) 955-2020

(414) 955-6166 (fax)


Continuing Medical Education

Mary Schafer


(414) 955-7840


Medical Education Coordinator



Director of Development - Ophthalmology

Gina Vrtochnick


(414) 955-5906 

Refer to Us - Consultation requests

Physician Referral Form (PDF)

Fax to (414) 955-0136


Emergent Requests

Within 48 hours call

(414) 955-2020



Vesper Williams


(414) 955-7862


Advanced Ocular Imaging Program


(414) 955-2647


Eye Institute Executive Director (Administrator)

Shannon Dreier


Eye Institute Google map location

Alcon HAWK